BiotechTube

GLA-SE

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Merkel Cell Carcinoma

Conditions

Merkel Cell Carcinoma

Trial Timeline

Jan 1, 2014 → Mar 1, 2018

NCT ID
NCT02035657

About GLA-SE

GLA-SE is a phase 1 stage product being developed by Merck for Merkel Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02035657. Target conditions include Merkel Cell Carcinoma.

What happened to similar drugs?

0 of 1 similar drugs in Merkel Cell Carcinoma were approved

Approved (0) Terminated (0) Active (1)
🔄Pembrolizumab (MK-3475)MerckPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02035657Phase 1Completed

Competing Products

20 competing products in Merkel Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
PembrolizumabMerckPhase 2
42
AvelumabMerckPre-clinical
26
Pembrolizumab (MK-3475)MerckPhase 3
40
domatinostat in combination with avelumabMerckPhase 2
27
Lenvatinib Oral Product + PembrolizumabMerckPhase 2
39
Pasireotide sub-cutaneous formulation + Pasireotide lon acting release formulationNovartisPhase 1
29
NivolumabBristol Myers SquibbPhase 2
35
Nivolumab + IpilimumabBristol Myers SquibbPhase 2
39
Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combinationBristol Myers SquibbPhase 2
42
Cemiplimab-RwlcSanofiPhase 1
33
vidutolimod + cemiplimabRegeneron PharmaceuticalsPhase 2
27
Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles + Placebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.Regeneron PharmaceuticalsPhase 2
42
Retifanlimab + Tuparstobart + VerzistobartIncytePhase 2
36
RetifanlimabIncytePhase 2
32
CabozantinibExelixisPhase 2
24
Avelumab + N-803 + haNK™ImmunityBioPhase 2
24
aNK (NK-92) + aNK (NK-92) + N-803ImmunityBioPhase 2
24
Avelumab + Bevacizumab + Capecitabine + Cisplatin + Cyclophosphamide + 5-fluorouracil + Leucovorin + nab-Paclitaxel + omega-3-acid ethyl esters + ALT-803 + ETBX-051 + ETBX-061 + GI-6301 + haNKImmunityBioPhase 1/2
21
XmAb18087 + XmAb18087 ± PembrolizumabICON plc.Phase 1/2
21
Arm A: F16IL2 in combination with paclitaxel + Arm B: PaclitaxelImmaticsPhase 2
21